Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) had its price target decreased by equities research analysts at HC Wainwright from $4.00 to $2.00 in a report issued on Monday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. HC Wainwright‘s price target would indicate a potential upside of 43.88% from the stock’s current price.
A number of other analysts have also commented on the company. UBS Group set a $4.00 price target on Aardvark Therapeutics in a research note on Monday, October 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aardvark Therapeutics in a research report on Tuesday, September 29th. Royal Bank Of Canada set a $2.50 price objective on shares of Aardvark Therapeutics in a report on Friday. Wall Street Zen raised shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Aardvark Therapeutics in a research report on Monday, October 12th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $11.28.
View Our Latest Stock Analysis on AARD
Aardvark Therapeutics Price Performance
Shares of NASDAQ AARD opened at $1.39 on Monday. The company has a market cap of $30.41 million, a price-to-earnings ratio of -0.43 and a beta of 3.80. The firm’s fifty day moving average is $5.26 and its 200 day moving average is $5.27. Aardvark Therapeutics has a 52 week low of $1.39 and a 52 week high of $16.60.
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21. Equities research analysts anticipate that Aardvark Therapeutics will post -3.05 earnings per share for the current year.
Insiders Place Their Bets
In other Aardvark Therapeutics news, insider Nelson Sun sold 62,000 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $5.18, for a total value of $321,160.00. Following the completion of the transaction, the insider owned 35,475 shares in the company, valued at approximately $183,760.50. This represents a 63.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 17.80% of the stock is currently owned by insiders.
Institutional Trading of Aardvark Therapeutics
A number of hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its holdings in shares of Aardvark Therapeutics by 30.8% during the 1st quarter. Bank of New York Mellon Corp now owns 29,320 shares of the company’s stock valued at $111,000 after buying an additional 6,905 shares in the last quarter. Susquehanna International Group LLP bought a new position in shares of Aardvark Therapeutics in the 2nd quarter worth about $138,000. Ieq Capital LLC purchased a new position in Aardvark Therapeutics during the 2nd quarter valued at about $221,000. J. Goldman & Co LP purchased a new position in Aardvark Therapeutics during the 2nd quarter valued at about $233,000. Finally, Renaissance Technologies LLC bought a new stake in Aardvark Therapeutics during the first quarter worth about $267,000.
Aardvark Therapeutics Company Profile
Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic diseases and other conditions involving appetite regulation. The company’s approach is based on activating bitter taste receptors in the gastrointestinal tract to stimulate the release of gut hormones associated with satiety and metabolic control.
Aardvark’s lead investigational product, ARD-101, is an orally administered, broad-spectrum bitter taste receptor agonist.
Read More
- Five stocks we like better than Aardvark Therapeutics
- Broadcom’s AI Chip Business Is Booming, But Alphabet’s Strategy Highlights 2 Key Risks
- Amazon’s $350 Price Target Faces a Big Earnings Test
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
